Pharming (PHAR)

What Moves the Stock

1. 01RUCONEST volume growth in European markets (Germany, Netherlands, UK represent 60%+ of ex-US sales)
2. 02Leniolisib regulatory milestones and FDA/EMA approval timelines for APDS (activated PI3K delta syndrome, estimated 1-2 per million prevalence)
3. 03US market dynamics including Takeda's RUCONEST promotional efforts and competitive positioning versus prophylactic HAE therapies
4. 04M&A speculation given attractive rare disease asset profile and potential acquirer interest from larger biopharma
5. 05Clinical trial readouts for pipeline complement inhibitors and expansion indications
6. 06RUCONEST product sales in Europe (~60-65% of revenue, direct commercial operations)
7. 07RUCONEST US royalties from Takeda partnership (~25-30% of revenue, mid-teens royalty rate)
8. 08Out-licensing and collaboration revenue (~5-10%, includes milestone payments)

PHAR Chart

My Notes

• growth - Investors are attracted to rare disease commercial-stage biotech with 21% revenue growth, pipeline optionality in leniolisib…
• Rising rates create moderate headwinds through two channels: (1) Higher discount rates compress biotech valuation multiples…
• Watch on earnings: RUCONEST quarterly prescription volume trends in top 5 European markets (Germany, Netherlands, UK, France, Italy), Leniolisib FDA PDUFA date and EMA CHMP opinion timing (expected H2 2026 based on typical review timelines), Takeda US royalty revenue trajectory as proxy for RUCONEST competitive positioning versus TAKHZYRO/ORLADEYO.